Bavituximab is just too big in my opinion for little Avid to handle the demand for US alone. Maybe at first but after frontline and breast are approved based on ORR in short time the demand will be too great.
A good problem to have.
Bavituximab will be the next Avastin marketing wise. But Bavi will be efficacious with almost no S/E.
News 
Market Data 
Discover 
AI
